Terms: = Bone cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
120 results:
1. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.
Del Dosso A; Tadevosyan E; Berenson JR
Oncotarget; 2024 Feb; 15():65-75. PubMed ID: 38319731
[TBL] [Abstract] [Full Text] [Related]
2. Regulatory function and mechanism research for m6A modification WTAP via SUCLG2-AS1- miR-17-5p-jak1 axis in AML.
Liu M; Yu B; Tian Y; Li F
BMC Cancer; 2024 Jan; 24(1):98. PubMed ID: 38233760
[TBL] [Abstract] [Full Text] [Related]
3. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract] [Full Text] [Related]
4. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/jak1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract] [Full Text] [Related]
5. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract] [Full Text] [Related]
6. Energy expenditure in myelofibrosis patients treated with a jak1/2 inhibitor.
Tremblay D; Dougherty M; Mascarenhas J; Gallagher EJ
Front Endocrinol (Lausanne); 2023; 14():1141029. PubMed ID: 37455900
[TBL] [Abstract] [Full Text] [Related]
7. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract] [Full Text] [Related]
8. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract] [Full Text] [Related]
9. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
[TBL] [Abstract] [Full Text] [Related]
10. IFN-γR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease.
Lu C; Ma H; Song L; Wang H; Wang L; Li S; Lagana SM; Sepulveda AR; Hoebe K; Pan SS; Yang YG; Lentzsch S; Mapara MY
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36445781
[TBL] [Abstract] [Full Text] [Related]
11. Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes.
Bolouri H; Ries RE; Wiedeman AE; Hylkema T; Scheiding S; Gersuk VH; O'Brien K; Nguyen QA; Smith JL; Alice Long S; Meshinchi S
Nat Commun; 2022 Nov; 13(1):7186. PubMed ID: 36418348
[TBL] [Abstract] [Full Text] [Related]
12. Management of polycythemia vera: A survey of treatment patterns in Italy.
Palumbo GA; Breccia M; Baratè C; Bonifacio M; Elli EM; Iurlo A; Pugliese N; Rossi E; Guglielmelli P; Palandri F
Eur J Haematol; 2023 Feb; 110(2):161-167. PubMed ID: 36319575
[TBL] [Abstract] [Full Text] [Related]
13. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
14. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo TK; Mendler JH; Itzykson R; Kishtagari A; Solary E; Seegmiller AC; Gerds AT; Ayers GD; Dezern AE; Nazha A; Valent P; van de Loosdrecht AA; Onida F; Pleyer L; Cirici BX; Tibes R; Geissler K; Komrokji RS; Zhang J; Germing U; Steensma DP; Wiseman DH; Pfeilstöecker M; Elena C; Cross NCP; Kiladjian JJ; Luebbert M; Mesa RA; Montalban-Bravo G; Sanz GF; Platzbecker U; Patnaik MM; Padron E; Santini V; Fenaux P; Savona MR;
BMC Cancer; 2022 Sep; 22(1):1013. PubMed ID: 36153475
[TBL] [Abstract] [Full Text] [Related]
15. The jak1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Xu N; Yu E; Ng N; Li M; Bujarski S; Hekmati A; Nassir I; Hekmati T; Yu J; Daniely D; Wang CS; Kim C; Chen H; Berenson JR
Hematol Oncol; 2023 Aug; 41(3):578-582. PubMed ID: 36043430
[TBL] [Abstract] [Full Text] [Related]
16. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
He Y; Luo W; Liu Y; Wang Y; Ma C; Wu Q; Tian P; He D; Jia Z; Lv X; Ma YS; Yang H; Xu K; Zhang X; Xiao Y; Zhang P; Liang Y; Fu D; Yao F; Hu G
J Clin Invest; 2022 Oct; 132(20):. PubMed ID: 36006737
[TBL] [Abstract] [Full Text] [Related]
17. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.
Breccia M; Palandri F; Guglielmelli P; Palumbo GA; Malato A; Mendicino F; Ricco A; Sant'Antonio E; Tiribelli M; Iurlo A
Curr Oncol; 2022 Jul; 29(7):4970-4980. PubMed ID: 35877255
[TBL] [Abstract] [Full Text] [Related]
18. Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
Yi G; Huang Z; Huang Z; Wang Y; Deng W; Zheng S; Li T
Front Immunol; 2022; 13():914265. PubMed ID: 35874753
[TBL] [Abstract] [Full Text] [Related]
19. Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
[TBL] [Abstract] [Full Text] [Related]
20. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract] [Full Text] [Related]
[Next]
